In severe asthma with an eosinophilic phenotype, depemokimab improved exacerbations, but not quality of life, at 52 wk

被引：0
|
作者：
McDonald, Christine F. [1 ,2 ]
机构：
[1] Austin Hosp, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
来源：
ANNALS OF INTERNAL MEDICINE | 2025年 / 178卷 / 01期
关键词：
D O I：
10.7326/ANNALS-24-03437-JC
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Clinical Impact Ratings GIM/FP/GP: Allerg & Immunol: Pulmonology:
引用
收藏
页码：JC8 / JC8
页数：1
相关论文
共 50 条
  • [1] Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
    Jackson, David J.
    Wechsler, Michael E.
    Jackson, Daniel J.
    Bernstein, David
    Korn, Stephanie
    Pfeffer, Paul E.
    Chen, Ruchong
    Saito, Junpei
    Martinez, Gustavo de Luiz
    Dymek, Lucyna
    Jacques, Loretta
    Bird, Nicholas
    Schalkwijk, Stein
    Smith, Douglas
    Howarth, Peter
    Pavord, Ian D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [2] Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
    Jackson, David J.
    Wechsler, Michael E.
    Jackson, Daniel J.
    Bernstein, David
    Korn, Stephanie
    Pfeffer, Paul E.
    Chen, Ruchong
    Saito, Junpei
    de Luiz Martinez, Gustavo
    Dymek, Lucyna
    Jacques, Loretta
    Bird, Nicholas
    Schalkwijk, Stein
    Smith, Douglas
    Howarth, Peter
    Pavord, Ian D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (24): : 2337 - 2349
  • [3] Mepolizumab, quality of life, and severe eosinophilic asthma
    Pavord, Ian D.
    LANCET RESPIRATORY MEDICINE, 2017, 5 (05): : 362 - 363
  • [4] Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma
    Russell, Richard
    Brightling, Christopher
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (06) : 607 - 617
  • [5] Impact Of Asthma Exacerbations On Health Related Quality Of Life In Patients With Severe Asthma
    Nelsen, L. M.
    Gunsoy, N.
    Cockle, S. M.
    Albers, F. C.
    Jones, P. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [6] Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX)
    McDowell, Pamela Jane
    Diver, Sarah
    Yang, Jieqiong Freda
    Borg, Catherine
    Busby, John
    Brown, Vanessa
    Shrimanker, Rahul
    Cox, Ciara
    Brightling, Christopher
    Chaudhuri, Rekha
    Pavord, Ian
    Heaney, Liam
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [7] Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy
    Howarth, Peter
    Chupp, Geoffrey
    Nelsen, Linda M.
    Bradford, Eric S.
    Bratton, Daniel J.
    Smith, Steven G.
    Albers, Frank C.
    Brusselle, Guy
    Bachert, Claus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (06) : 1713 - +
  • [8] Dupilumab Reduced Severe Exacerbations and Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma with an Eosinophilic Phenotype Across Baseline IgE Levels: LIBERTY ASTHMA QUEST Study
    Carr, W. W.
    Corren, J.
    Casale, T. B.
    Daizadeh, N.
    Khan, A. H.
    Kamat, S.
    Deniz, Y.
    Rowe, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [9] Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
    Ortega, Hector
    Liu, Mark
    Pavord, Ian
    Brusselle, Guy
    FitzGerald, J. Mark
    Chetta, Alfredo
    Katz, Lynn
    Keene, Oliver
    Yancey, Steven
    Chanez, Pascal
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [10] Impact of Reslizumab on Duration of Exacerbations in Patients with Severe Eosinophilic Asthma
    Manning, Michael E.
    Garin, Margaret
    Jiang, Bo
    Sun, Shawn X.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB17 - AB17
12345